Business · 03/08/1998Updated: 10/17/2026 · 1 min read
FDA Extends Comment Period for In Vivo Radiopharmaceutical Regulations
Summary
The Food and Drug Administration (FDA) has extended the comment period for a proposed rule on in vivo radiopharmaceuticals used for diagnosis and monitoring until October 15, 1998, to allow interested persons more time to submit comments on the proposed regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →